{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:44:41Z","timestamp":1790196281112,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.breast.2023.07.010","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T23:35:06Z","timestamp":1690241706000},"page":"63-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9123-4931","authenticated-orcid":false,"given":"Anna","family":"Nordenskj\u00f6ld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-0949","authenticated-orcid":false,"given":"Helena","family":"Fohlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils-Olof","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Fornander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hatschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Lindman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Wallgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"St\u00e5l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Nordenskj\u00f6ld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2023.07.010_bib1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Early Breast Cancer Trialists' Collaborative","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2023.07.010_bib2","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jnci\/88.21.1543","article-title":"Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group","volume":"88","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2023.07.010_bib3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2023.07.010_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(89)91141-0","article-title":"Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers","volume":"1","author":"Fornander","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2023.07.010_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/02841869209088914","article-title":"Long-term effects of adjuvant tamoxifen and\/or radiotherapy. The south Sweden breast cancer trial","volume":"31","author":"Ryden","year":"1992","journal-title":"Acta Oncol"},{"key":"10.1016\/j.breast.2023.07.010_bib6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/0284186X.2016.1273547","article-title":"Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen","volume":"56","author":"Rosell","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.breast.2023.07.010_bib8","series-title":"Statistics in practice: analalysing survival data from clinical trials and obserational studies","first-page":"331","article-title":"Competing risks","author":"Marubini","year":"1995"},{"key":"10.1016\/j.breast.2023.07.010_bib9","series-title":"StataCorp. Stata statistical software: release 13 collage","year":"2013"},{"key":"10.1016\/j.breast.2023.07.010_bib10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"suppl","key":"10.1016\/j.breast.2023.07.010_bib11","article-title":"aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6953 women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.07.010_bib12","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdz289","article-title":"Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial","volume":"30","author":"Bartlett","year":"2019","journal-title":"Ann Oncol : Off J European Soc Med Oncol \/ ESMO."},{"key":"10.1016\/j.breast.2023.07.010_bib13","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1200\/JCO.2015.65.6272","article-title":"Two years of adjuvant tamoxifen provides a survival benefit compared with No systemic treatment in premenopausal patients with primary breast cancer: long-term follow-up (> 25 years) of the phase III SBII:2pre trial","volume":"34","author":"Ekholm","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.07.010_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1158\/1078-0432.CCR-19-1038","article-title":"Comprehensive transcriptomic profiling identifies breast cancer patients who may Be spared adjuvant systemic therapy","volume":"26","author":"Sjostrom","year":"2020","journal-title":"Clin Cancer Res : an Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.breast.2023.07.010_bib15","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1001\/jamaoncol.2017.1261","article-title":"Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades","volume":"3","author":"Esserman","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2023.07.010_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/02841860601034834","article-title":"Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer","volume":"46","author":"Rutqvist","year":"2007","journal-title":"Acta Oncol"},{"key":"10.1016\/j.breast.2023.07.010_bib17","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/bjc.2011.145","article-title":"Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial","volume":"104","author":"Jerevall","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2023.07.010_bib18","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2023.07.010_bib19","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2023.07.010_bib20","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/cncr.25638","article-title":"Lung cancer mortality risk among breast cancer patients treated with anti-estrogens","volume":"117","author":"Bouchardy","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2023.07.010_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.canep.2017.02.010","article-title":"Antiestrogen use in breast cancer patients reduces the risk of subsequent lung cancer: a population-based study","volume":"48","author":"Chu","year":"2017","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.breast.2023.07.010_bib22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.maturitas.2009.11.027","article-title":"Menopausal hormone therapy and risk of lung cancer-Systematic review and meta-analysis","volume":"65","author":"Greiser","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.breast.2023.07.010_bib23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/JTO.0b013e31827d525c","article-title":"Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer","volume":"8","author":"Garon","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.breast.2023.07.010_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1530\/ERC-18-0328","article-title":"Lymph\/angiogenesis contributes to sex differences in lung cancer through oestrogen receptor alpha signalling","volume":"26","author":"Dubois","year":"2019","journal-title":"Endocr Relat Cancer"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623005337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977623005337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:47:08Z","timestamp":1760777228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977623005337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":23,"alternative-id":["S0960977623005337"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2023.07.010","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2856174\/v1","asserted-by":"object"}]},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2023.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}